SCHEMBL7043798

SCHEMBL7043798

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](c5ccccc5C(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OSBP P22059 4/20 0.66
RORC P51449 3/20 0.66
USP2 O75604 2/20 0.66
CYP46A1 Q9Y6A2 2/20 0.66
OSBP2 Q969R2 2/20 0.66
LMNA P02545 1/20 0.66
ABCB1 P08183 1/20 0.66
POLA1 P09884 1/20 0.64
NR1H3 Q13133 4/20 0.57
EPHA2 P29317 1/20 0.57
GRIN1 Q05586 3/20 0.56
GRIN2A Q12879 3/20 0.56
FNTA P49354 1/20 0.55
FNTB P49356 1/20 0.55
CRYAB P02511 1/20 0.54
HMGCR P04035 1/20 0.54
ITGB3 P05106 1/20 0.54
ITGAV P06756 1/20 0.54
SREBF2 Q12772 1/20 0.54
NPC1L1 Q9UHC9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7043800 1.00 OSBP (0.66) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL11656047 0.94 OSBP (0.66) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL11656049 0.92 OSBP (0.66) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL9446912 0.90 POLA1 (0.64) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL6903726 0.89 OSBP (0.62) OSBPRORCUSP2CYP46A1OSBP2
Cholesterol SCHEMBL1296896 0.89 OSBP (0.82) OSBPRORCUSP2CYP46A1OSBP2
Cholesterol SCHEMBL29033213 0.89 OSBP (0.82) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL4432535 0.88 OSBP (0.60) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL6904293 0.88 OSBP (0.62) OSBPRORCUSP2CYP46A1OSBP2
SCHEMBL10334278 0.87 OSBP (0.59) OSBPRORCUSP2CYP46A1OSBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465592-B2 Structured encapsulated silicon-containing particles SISAF LIMITED (GB) 2025-11-11 US claimed
EP-3946279-B1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES SISAF LTD (GB) 2025-07-23 EP claimed
US-20220184038-A1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES SISAF LIMITED (GB) 2022-06-16 US claimed
EP-3946279-A1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES Sisaf Ltd (GB) 2022-02-09 EP claimed
WO-2020193998-A1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES SISAF LIMITED (GB) 2020-10-01 WO claimed
EP-3714879-A1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES Sisaf Ltd (GB) 2020-09-30 EP claimed
EP-2507310-B1 MODIFIED RUBBER COMPOSITIONS AND METHODS OF PREPARATION BRIDGESTONE CORP (JP) 2017-09-06 EP claimed
EP-0988031-B1 PHARMACEUTICAL COMPOSITION IN FORM OF SOLID LIPIDIC MICROPARTICLES SUITABLE TO PARENTERAL ADMINISTRATION GASCO MARIA ROSA (IT) 2003-04-02 EP claimed
US-6238694-B1 Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration GASCO MARIA ROSA (IT) 2001-05-29 US claimed
EP-0988031-A1 PHARMACEUTICAL COMPOSITION IN FORM OF SOLID LIPIDIC MICROPARTICLES SUITABLE TO PARENTERAL ADMINISTRATION Gasco, Maria Rosa (IT) 2000-03-29 EP claimed
WO-1998056362-A1 PHARMACEUTICAL COMPOSITION IN FORM OF SOLID LIPIDIC MICROPARTICLES SUITABLE TO PARENTERAL ADMINISTRATION GASCO MARIA ROSA (IT) 1998-12-17 WO claimed
EP-0404639-B1 Cholesteric liquid composition and color-forming liquid crystal composite products SHINKO ELECTRIC WORKS CO LTD (JP) 1995-08-30 EP claimed
EP-0400220-B1 Laminated article for identification purposes AGFA GEVAERT NV (BE) 1994-08-31 EP claimed
US-12465592-B2 Structured encapsulated silicon-containing particles SISAF LIMITED (GB) 2025-11-11 US disclosed
EP-3946279-B1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES SISAF LTD (GB) 2025-07-23 EP disclosed
US-12001091-B2 Spatially variable liquid crystal diffraction gratings MAGIC LEAP, INC. (US) 2024-06-04 US disclosed
US-5510913-A Head-up display system where polarized light from a display impinges on a glass plate containing twisted nematic liquid crystal at the plate's Brewsters angle CENTRAL GLASS COMPANY, LIMITED (JP) 1996-04-23 US disclosed
EP-0580143-A2 Head-up display system CENTRAL GLASS COMPANY, LIMITED (JP) 1994-01-26 EP disclosed
US-4420224-A Liquid crystal display cell, process for its production and cell plate BBC BROWN, BOVERI & COMPANY LIMITED (CH) 1983-12-13 US disclosed
EP-0025037-B1 LIQUID CRYSTAL DISPLAY CELL AND PROCESS FOR MANUFACTURING THEREOF BBC Aktiengesellschaft Brown, Boveri & Cie. (CH) 1983-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465592-B2 Structured encapsulated silicon-containing particles SGMS1, SGMS2, SMURF1 OSBP 182/4885RORC 1295/4885USP2 1367/4885
US-20220184038-A1 STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES SGMS1, SGMS2, SMURF1 OSBP 182/4885RORC 1295/4885USP2 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.